Skye’s cannabinoid drug fails in mid-stage obesity trialnews2025-10-06T11:00:10+00:00October 6th, 2025|Endpoints News|
AstraZeneca, Daiichi Sankyo report Phase 3 win for Datroway in triple negative breast cancernews2025-10-06T10:14:51+00:00October 6th, 2025|Endpoints News|
Trogenix raises $95M Series A as brain cancer program nears clinicnews2025-10-05T23:01:22+00:00October 5th, 2025|Endpoints News|
Pfizer’s ‘most favored nation’ deal; Metsera’s obesity data; Takeda stops cell therapy work; and morenews2025-10-04T10:00:39+00:00October 4th, 2025|Endpoints News|
HHS reorganization suit must proceed despite government shutdown, court rulesnews2025-10-03T19:37:01+00:00October 3rd, 2025|Endpoints News|
Legal pressure builds around FDA’s new DTC pharma ad crackdownnews2025-10-03T18:51:43+00:00October 3rd, 2025|Endpoints News|
BridgeBio’s GondolaBio bet skirts industry’s focus on small pipelinesnews2025-10-03T18:37:53+00:00October 3rd, 2025|Endpoints News|
FDA OKs Zepzelca-Tecentriq combo; CSL Vifor’s layoffsnews2025-10-03T15:07:31+00:00October 3rd, 2025|Endpoints News|
Rocket withdraws FDA application for rare blood disorder gene therapynews2025-10-03T14:56:01+00:00October 3rd, 2025|Endpoints News|
Ovid gets a boost from Phase 1 data, $81M+ PIPE financingnews2025-10-03T13:52:25+00:00October 3rd, 2025|Endpoints News|
